Femasys Inc.

Femasys Inc. is a woman-founded and led biomedical company dedicated to enhancing women's healthcare through innovative, minimally invasive, non-surgical technologies. The company focuses on addressing significant needs in infertility, contraception, and cancer diagnostics. With a mission to provide safe and accessible solutions, Femasys aims to improve patient care and health standards globally, supported by a robust portfolio of approximately 200 patents. The company develops a range of therapeutic and diagnostic products using a proprietary non-surgical delivery platform. Key offerings include FemaSeed, an intratubal insemination device; FemVue, an ultrasound-based diagnostic tool; FemBloc, a candidate for non-surgical birth control; and FemCerv, a tissue sampler for cervical cancer diagnosis. Femasys emphasizes safety and efficiency in its in-office approaches, with a commitment to empowering women throughout their reproductive journeys. The company is publicly traded on NASDAQ under the ticker FEMY.